Although quantitative real-time PCR analysis presented that the in vivo administration of AmC and AaC downregulated the expression of Bcl-2 and Bcl-xL while upregulated Bax, Cyt C, caspase-3, and caspase-9 of the S180 ascites tumor cells [37], the present PgE and HaE each in vitro downregulated the expression of Bcl-2 while on the other hand upregulated Bax and caspase-3 in HepG2 cancer cell line, whereas there is another in vivo study that stated the enhanced antiangiogenic activity associated with inhibition of VEGFR2 signaling of PE on S180 tumor cancer cells [35, 36]. This evidence concerns the gene BCL2L1 and cancer.